SCHEMBL16892829

SCHEMBL16892829

Cc1ccc(S(=O)(=O)O)c(C2CCSCC2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.35
EPHX2 P34913 4/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
GAA P10253 2/20 0.32
MAPT P10636 2/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
POLB P06746 1/20 0.32
RECQL P46063 1/20 0.32
CASP6 P55212 1/20 0.32
KMT2A Q03164 1/20 0.32
ELAVL1 Q15717 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
CHRNB2 P17787 1/20 0.32
CHRNA4 P43681 1/20 0.32
DRD2 P14416 1/20 0.32
DRD4 P21917 1/20 0.32
DRD3 P35462 1/20 0.32
MCOLN3 Q8TDD5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9335346 0.91 PTGDR2 (0.32) PTGDR2EPHX2L3MBTL1GAAMAPT
SCHEMBL10431891 0.91 PTGDR2 (0.32) PTGDR2EPHX2L3MBTL1GAAMAPT
SCHEMBL9101971 0.89 PTGDR2 (0.39) PTGDR2EPHX2L3MBTL1GAAMAPT
SCHEMBL5278348 0.86 PTGDR2 (0.47) PTGDR2EPHX2MAPTMEN1ALDH1A1
SCHEMBL30764027 0.86 PTGDR2 (0.43) PTGDR2EPHX2L3MBTL1CHRNB2CHRNA4
SCHEMBL2217850 0.84 PTGDR2 (0.46) PTGDR2EPHX2MAPTMEN1ALDH1A1
SCHEMBL361128 0.84 PTGDR2 (0.49) PTGDR2EPHX2GAAMAPTMEN1
SCHEMBL3387056 0.83 PTGDR2 (0.36) PTGDR2EPHX2L3MBTL1GAAMAPT
SCHEMBL16712212 0.82 CHRNB2 (0.43) PTGDR2EPHX2L3MBTL1GAAMAPT
SCHEMBL28966936 0.82 HTR6 (0.44) MEN1ALDH1A1KMT2ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368161-A1 CYCLOPROPANECARBOXAMIDE-CONTAINING COMPOUNDS AND APPLICATION THEREOF CGENETECH (SUZHOU,CHINA) CO., LTD. (CN) 2024-11-07 US disclosed
EP-4446322-A1 CYCLOPROPANAMIDE-CONTAINING COMPOUND AND USE THEREOF CGeneTech (Suzhou, China) Co., Ltd. (CN) 2024-10-16 EP disclosed
CN-116496268-A Cyclopropylamide-containing compound and application thereof 盛世泰科生物医药技术(苏州)有限公司 2023-07-28 CN disclosed
WO-2023138550-A1 CYCLOPROPANAMIDE-CONTAINING COMPOUND AND USE THEREOF 盛世泰科生物医药技术(苏州)有限公司 2023-07-27 WO disclosed
EP-2894151-B1 IMIDAZOLINE DERIVATIVES, PREPARATION METHODS THEREOF, AND THEIR APPLICATIONS IN MEDICINE Shanghai hengrui pharmaceutical co ltd (CN) 2020-11-11 EP disclosed
EP-3423446-B1 NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS Bayer Pharma AG (DE) 2020-09-16 EP disclosed
CN-111032641-A Substituted 5-cyanoindole compounds and uses thereof 诺华股份有限公司 2020-04-17 CN disclosed
EP-3423446-A1 NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS Bayer Pharma Aktiengesellschaft (DE) 2019-01-09 EP disclosed
US-9895355-B2 Methods of treating androgen receptor-mediated disorders with imidazoline derivatives Shanghai Hengru Pharmaceutical Co., Ltd. (CN) 2018-02-20 US disclosed
US-20170128422-A1 METHODS OF TREATING ANDROGEN RECEPTOR-MEDIATED DISORDERS WITH IMIDAZOLINE DERIVATIVES Shanghai hengrui pharmaceutical co ltd (CN) 2017-05-11 US disclosed
US-9586947-B2 Imidazoline derivatives, preparation methods thereof, and their applications in medicine SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2017-03-07 US disclosed
US-20150225381-A1 IMIDAZOLINE DERIVATIVES, PREPARATION METHODS THEREOF, AND THEIR APPLICATIONS IN MEDICINE JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2015-08-13 US disclosed
EP-2894151-A1 IMIDAZOLINE DERIVATIVES, PREPARATION METHODS THEREOF, AND THEIR APPLICATIONS IN MEDICINE Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) 2015-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368161-A1 CYCLOPROPANECARBOXAMIDE-CONTAINING COMPOUNDS AND APPLICATION THEREOF MCL1, BCL9, BCL9L PTGDR2 45/4885EPHX2 275/4885L3MBTL1 4722/4885
US-20170128422-A1 METHODS OF TREATING ANDROGEN RECEPTOR-MEDIATED DISORDERS WITH IMIDAZOLINE DERIVATIVES NR5A1, ESRRA, ESRRB PTGDR2 194/4885EPHX2 4259/4885L3MBTL1 4064/4885
US-20150225381-A1 IMIDAZOLINE DERIVATIVES, PREPARATION METHODS THEREOF, AND THEIR APPLICATIONS IN MEDICINE AR, KLK3, NR5A1 PTGDR2 136/4885EPHX2 3678/4885L3MBTL1 4881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.